Literature DB >> 21724588

GPR56 Regulates VEGF production and angiogenesis during melanoma progression.

Liquan Yang1, Guangchun Chen, Sonali Mohanty, Glynis Scott, Fabeha Fazal, Arshad Rahman, Shahinoor Begum, Richard O Hynes, Lei Xu.   

Abstract

Angiogenesis is a critical step during cancer progression. The VEGF is a major stimulator for angiogenesis and is predominantly contributed by cancer cells in tumors. Inhibition of the VEGF signaling pathway has shown promising therapeutic benefits for cancer patients, but adaptive tumor responses are often observed, indicating the need for further understanding of VEGF regulation. We report that a novel G protein-coupled receptor, GPR56, inhibits VEGF production from the melanoma cell lines and impedes melanoma angiogenesis and growth, through the serine threonine proline-rich segment in its N-terminus and a signaling pathway involving protein kinase Cα. We also present evidence that the two fragments of GPR56, which are generated by autocatalyzed cleavage, played distinct roles in regulating VEGF production and melanoma progression. Finally, consistent with its suppressive roles in melanoma progression, the expression levels of GPR56 are inversely correlated with the malignancy of melanomas in human subjects. We propose that components of the GPR56-mediated signaling pathway may serve as new targets for antiangiogenic treatment of melanoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21724588      PMCID: PMC3156271          DOI: 10.1158/0008-5472.CAN-10-4543

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  Essential regulation of CNS angiogenesis by the orphan G protein-coupled receptor GPR124.

Authors:  Frank Kuhnert; Michael R Mancuso; Amir Shamloo; Hsiao-Ting Wang; Vir Choksi; Mareike Florek; Hua Su; Marcus Fruttiger; William L Young; Sarah C Heilshorn; Calvin J Kuo
Journal:  Science       Date:  2010-11-12       Impact factor: 47.728

2.  Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR.

Authors:  U Graeven; W Fiedler; S Karpinski; S Ergün; N Kilic; U Rodeck; W Schmiegel; D K Hossfeld
Journal:  J Cancer Res Clin Oncol       Date:  1999-11       Impact factor: 4.553

3.  Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206.

Authors:  A Grützkau; S Krüger-Krasagakes; H Baumeister; C Schwarz; H Kögel; P Welker; U Lippert; B M Henz; A Möller
Journal:  Mol Biol Cell       Date:  1998-04       Impact factor: 4.138

4.  Disease-associated mutations affect GPR56 protein trafficking and cell surface expression.

Authors:  Zhaohui Jin; Ian Tietjen; Lihong Bu; Liqun Liu-Yesucevitz; Shantanu K Gaur; Christopher A Walsh; Xianhua Piao
Journal:  Hum Mol Genet       Date:  2007-06-18       Impact factor: 6.150

5.  High-grade glioma before and after treatment with radiation and Avastin: initial observations.

Authors:  Ingeborg Fischer; Clare H Cunliffe; Robert J Bollo; Shahzad Raza; David Monoky; Luis Chiriboga; Erik C Parker; John G Golfinos; Patrick J Kelly; Edmond A Knopp; Michael L Gruber; David Zagzag; Ashwatha Narayana
Journal:  Neuro Oncol       Date:  2008-08-12       Impact factor: 12.300

Review 6.  Tumorigenesis and the angiogenic switch.

Authors:  Gabriele Bergers; Laura E Benjamin
Journal:  Nat Rev Cancer       Date:  2003-06       Impact factor: 60.716

7.  Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.

Authors:  Domingo G Perez; Vera J Suman; Tom R Fitch; Thomas Amatruda; Roscoe F Morton; Shamim Z Jilani; Costas L Constantinou; James R Egner; Lisa A Kottschade; Svetomir N Markovic
Journal:  Cancer       Date:  2009-01-01       Impact factor: 6.860

8.  Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation.

Authors:  Angela Kadenhe-Chiweshe; Joey Papa; Kimberly W McCrudden; Jason Frischer; Jae-O Bae; Jianzhong Huang; Jason Fisher; Jay H Lefkowitch; Nikki Feirt; John Rudge; Jocelyn Holash; George D Yancopoulos; Jessica J Kandel; Darrell J Yamashiro
Journal:  Mol Cancer Res       Date:  2008-01       Impact factor: 5.852

9.  BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module.

Authors:  Daeho Park; Annie-Carole Tosello-Trampont; Michael R Elliott; Mingjian Lu; Lisa B Haney; Zhong Ma; Alexander L Klibanov; James W Mandell; Kodi S Ravichandran
Journal:  Nature       Date:  2007-11-15       Impact factor: 49.962

10.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

View more
  50 in total

1.  Activation of myeloid cell-specific adhesion class G protein-coupled receptor EMR2 via ligation-induced translocation and interaction of receptor subunits in lipid raft microdomains.

Authors:  Yi-Shu Huang; Nien-Yi Chiang; Ching-Hsun Hu; Cheng-Chih Hsiao; Kai-Fong Cheng; Wen-Pin Tsai; Simon Yona; Martin Stacey; Siamon Gordon; Gin-Wen Chang; Hsi-Hsien Lin
Journal:  Mol Cell Biol       Date:  2012-02-06       Impact factor: 4.272

Review 2.  Adhesion G Protein-Coupled Receptors: From In Vitro Pharmacology to In Vivo Mechanisms.

Authors:  Kelly R Monk; Jörg Hamann; Tobias Langenhan; Saskia Nijmeijer; Torsten Schöneberg; Ines Liebscher
Journal:  Mol Pharmacol       Date:  2015-05-08       Impact factor: 4.436

3.  The orphan adhesion G protein-coupled receptor GPR97 regulates migration of lymphatic endothelial cells via the small GTPases RhoA and Cdc42.

Authors:  Nadejda Valtcheva; Adriana Primorac; Giorgia Jurisic; Maija Hollmén; Michael Detmar
Journal:  J Biol Chem       Date:  2013-10-31       Impact factor: 5.157

Review 4.  Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy.

Authors:  Victoria Wu; Huwate Yeerna; Nijiro Nohata; Joshua Chiou; Olivier Harismendy; Francesco Raimondi; Asuka Inoue; Robert B Russell; Pablo Tamayo; J Silvio Gutkind
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

5.  Disease-associated extracellular loop mutations in the adhesion G protein-coupled receptor G1 (ADGRG1; GPR56) differentially regulate downstream signaling.

Authors:  Ayush Kishore; Randy A Hall
Journal:  J Biol Chem       Date:  2017-04-19       Impact factor: 5.157

Review 6.  Adhesion G protein-coupled receptors: signaling, pharmacology, and mechanisms of activation.

Authors:  Kevin J Paavola; Randy A Hall
Journal:  Mol Pharmacol       Date:  2012-07-20       Impact factor: 4.436

Review 7.  GPCRs and cancer.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Acta Pharmacol Sin       Date:  2012-01-23       Impact factor: 6.150

8.  Type IV collagen is an activating ligand for the adhesion G protein-coupled receptor GPR126.

Authors:  Kevin J Paavola; Harwin Sidik; J Bradley Zuchero; Michael Eckart; William S Talbot
Journal:  Sci Signal       Date:  2014-08-12       Impact factor: 8.192

Review 9.  The BAI subfamily of adhesion GPCRs: synaptic regulation and beyond.

Authors:  Jason R Stephenson; Ryan H Purcell; Randy A Hall
Journal:  Trends Pharmacol Sci       Date:  2014-03-15       Impact factor: 14.819

Review 10.  Adhesion G protein-coupled receptors in nervous system development and disease.

Authors:  Tobias Langenhan; Xianhua Piao; Kelly R Monk
Journal:  Nat Rev Neurosci       Date:  2016-07-28       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.